Healthcare >> Sector Roundtables >> May 29, 2000

Roundtable Forum: Outlook For Biotechnology

ROBERT TOTH, JR. is a Senior Analyst with the Prudential Vector Healthcare Group, covering biotechnology companies focusing on cancer therapeutics, genomic platforms, and neuroscience applications. He joined Prudential Securities via the July 1999 acquisition of Vector Securities International, Inc. Prior to joining Vector, Mr. Toth served as Business Development Analyst with the biotechnology company Connectics Corp. He received his BBA in Biology and Biochemistry from California State Polytechnic University, and an MBA from the University of Washington School of Business. Profile
PETER F. DRAKE, PhD is a Managing Director of Equity Research with Prudential Vector Healthcare Group, where he also serves as co-Founder and Executive Vice President of Vector Securities International. Previously, he served as a Senior Research Analyst covering biotechnology and biomedical products with Kidder, Peabody. Dr. Drake holds a Doctoral degree in Neurobiology and Biochemistry from Bryn Mawr College and a CBA from the Wharton School of Business at the University of Pennsylvania. Profile
JOHN S. SONNIER is a Senior Biotechnology Analyst with the Prudential Vector Healthcare Group, focusing on small, mid- and large-cap companies in the areas of infectious disease, transfusion medicine and neuroscience. He joined Prudential Securities via the July 1999 acquisition of Vector Securities International, Inc. Prior to joining Vector, Mr. Sonnier spent eight years in the pharmaceutical industry at Johnson & Johnson and Baxter and, most recently, as the Senior Healthcare Planning Manager at Baxter Healthcare Corporation, Biotech Group. He received his BS degree in Business from the University of Southern Mississippi. Profile
TWST: Peter, will you begin by telling us about the approach that the

Prudential Vector Healthcare Group takes to the biotechnology sector?

Mr. Drake: I'd be glad to. First of all, we take a